Maxpro Capital (NASDAQ:JMAC) announced this afternoon that its shareholders have approved its combination with biopharmaceutical firm Apollomics.
An aggregate of 10,804,097 shares of Maxpro’s common stock were present at yesterday’s special meeting. Holders of 8,024,976 shares of common stock approved the business combination, but the deal faced a bit of pushback with 2,779,121 shares voting against it.
In connection with the transaction, holders of 10,270,060 shares, or 99.228% of Maxpro’s trust, exercised their right to redeem their shares. Following the redemptions, the SPAC is left with 79,940 shares remaining.
The parties have not yet disclosed when the deal will be completed, but the combined company is expected to trade on the Nasdaq under the symbol “APLM” once it closes.
Maxpro Capital announced its $899 million deal with Apollomics in September 2022. The Foster City, California-based company is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.
ADVISORS
- ARC Group Limited is acting as financial advisor to Maxpro.
- EF Hutton is acting as capital market advisor to Maxpro.
- White & Case LLP is acting as legal counsel to Apollomics.
- Nelson Mullins Riley & Scarborough LLP is acting as legal counsel to Maxpro.
- Marshall & Stevens Transaction Advisory Services LLC is acting as the fairness opinion provider to the board of directors of Maxpro.
NMP Acquisition Corp. (NASDAQ:NMPAU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NMPAU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company that has a resilient business model with potential to scale up revenue. NMP’s management...
Cohen Circle Acquisition Corp. II (NASDAQ:CCIIU) announced the pricing of its $220 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIIU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company in the financial services technology (fintech) sector and fintech adjacent sectors that...
Indigo Acquisition Corp. (NASDAQ:INACU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “INACU”, Tuesday, July 1, 2025. The new SPAC plans to combine with an established, profitable company whose growth potential can benefit from its team’s expertise. Indigo’s management team is...
After a quiet June, July is set to be active throughout the month with nine de-SPACs and sponsors coming unlocked from their trading restrictions. This timing is most fortuitous for insurance investor Abacus Life (NASDAQ:ABL) and East Resources, which took it public in 2023, as it is the best performer of this group of companies...
Pyrophyte II (NYSE:PAII.U) has filed for a $175 million SPAC to dig for a natural resources target while the team’s first deal remains pending. The new SPAC is offering investors 1/2 warrants in each unit and it will have 24 months to complete a business combination without asking shareholders for an extension. It is the...